Aktienanalyse zu iSpecimen Inc (ISPC)ISPCiSpecimen Inc

iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting. It operates in the Technology sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

iSpecimen Inc. is not a good buy right now due to its declining financial performance and negative market sentiment. The stock has dropped 92.97% year-to-date and is currently trading at $0.80, significantly below its 52-week high of $27.44. The company has reported substantial losses, with a net income of -1,362,811 USD in Q2 2026 and a gross margin of only 45.18%. Furthermore, the RSI is at 41.12, indicating a lack of bullish momentum, and the stock has fallen 2.60% over the past five days. The primary risk is the company's ongoing financial instability, as evidenced by its negative net margins and reliance on public offerings to raise capital.